SCHEMBL14633643

SCHEMBL14633643

CNc1nc(Nc2cc(C)cc(S(C)(=O)=O)c2)ncc1-c1n[nH]c2c(F)c(F)ccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.39
CCNT1 O60563 2/20 0.39
CCNE1 P24864 2/20 0.39
CDK9 P50750 2/20 0.39
JAK1 P23458 3/20 0.37
JAK3 P52333 2/20 0.37
LRRK2 Q5S007 5/20 0.36
PTGS2 P35354 1/20 0.36
GLO1 Q04760 1/20 0.35
AURKA O14965 1/20 0.35
JAK2 O60674 1/20 0.35
GAK O14976 1/20 0.34
SYK P43405 1/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CCNB1 P14635 2/20 0.34
CCNA2 P20248 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34
CCNE2 O96020 1/20 0.34
CDK7 P50613 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2535221 0.94 JAK1 (0.39) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL14634077 0.90 JAK1 (0.40) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL14633563 0.89 CDK2 (0.39) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL14634093 0.89 CDK2 (0.41) CDK2CCNT1CCNE1CDK9JAK3
SCHEMBL14633760 0.86 CCNT1 (0.37) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL14633954 0.85 JAK3 (0.42) CDK2CCNT1CDK9JAK1JAK3
SCHEMBL14634045 0.85 JAK1 (0.38) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL2471137 0.84 CDK2 (0.36) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL14633508 0.84 JAK1 (0.38) CDK2CCNT1CCNE1CDK9JAK1
SCHEMBL2469164 0.84 RIPK2 (0.44) CDK2CDK9JAK1JAK3LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CDK2 22/4885CCNT1 331/4885CCNE1 340/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CDK2 1/4885CCNT1 282/4885CCNE1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.